Description: Autolus Therapeutics Ltd is a biopharmaceutical company. It is engaged in the development of next-generation programmed T cell therapies for the treatment of cancer. The company's pipeline includes AUTO1, AUTO2, AUTO3, AUTO4, and AUTO6.
Home Page: www.autolus.com
AUTL Technical Analysis
The MediaWorks
London,
W12 7FP
United Kingdom
Phone:
44 20 3829 6230
Officers
| Name | Title |
|---|---|
| Dr. Christian Martin Itin Ph.D. | CEO & Director |
| Dr. Martin Pule M.D., MBBS | Founder, Sr. VP & Chief Scientific Officer |
| Mr. Christopher Vann | Sr. VP & COO |
| Mr. David Brochu | Sr. VP & Chief Technical Officer |
| Mr. Andrew J. Oakley ACA, BEcon, MBA | Sr. Advisor |
| Mr. Brent Rice | Sr. VP, Chief Commercial Officer & Site Head of US |
| Dr. Edgar E. W. Braendle M.D., Ph.D. | Sr. VP & Chief Devel. Officer |
| Dr. Lucinda Crabtree Ph.D. | Chief Financial Officer |
| Ms. Olivia Manser | Director of Investor Relations |
| Dr. Chris Williams | Sr. VP of Corp. Devel. |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.0462 |
| Price-to-Sales TTM: | 62.0976 |
| IPO Date: | 2018-06-22 |
| Fiscal Year End: | September |
| Full Time Employees: | 324 |